License and Cooperation Agreement FOR PERIFOSINE by and between Zentaris AG Weismüllerstr. 45 60314 Frankfurt am Main Germany - herein “Zentaris” - and AOI Pharma, Inc. 750 Lexington Avenue, 26th Floor New York, New York 10022 USA - herein “AOI” -License and Cooperation Agreement • May 7th, 2010 • Aeterna Zentaris Inc. • Pharmaceutical preparations
Whereas, AOI desires to obtain certain licenses from Zentaris to develop and commercialize Perifosine under the aforesaid patents and know-how, and Zentaris is willing to grant to AOI such licenses;
EX-10.1 2 dex101.htm LICENSE AND COOPERATION AGREEMENT THE SYMBOL ‘*’ IS USED THROUGHOUT THIS EXHIBIT TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. LICENSE AND COOPERATION AGREEMENTLicense and Cooperation Agreement • May 5th, 2020 • New York
This License and Cooperation Agreement (the “Agreement”) is made and is effective as of this date of April 16, 1998 (“Effective Date”), between
License and Cooperation Agreement FOR PERIFOSINE by and between Zentaris AG Weismüllerstr. 45 60314 Frankfurt am Main Germany - herein "Zentaris" - and AOI Pharma, Inc. 750 Lexington Avenue, 26th Floor New York, New York 10022 USA - herein "AOI" -License and Cooperation Agreement • March 30th, 2004 • Keryx Biopharmaceuticals Inc • Pharmaceutical preparations
Whereas, AOI desires to obtain certain licenses from Zentaris to develop and commercialize Perifosine under the aforesaid patents and know-how, and Zentaris is willing to grant to AOI such licenses;
LICENSE AND COOPERATION AGREEMENTLicense and Cooperation Agreement • May 20th, 2010 • Cord Blood America, Inc. • Services-medical laboratories • California
THIS LICENSE AND COOPERATION AGREEMENT (this "Agreement"), effective as of March 31, 2010 (the "Effective Date"), is entered into by and among, on the one hand, Cord Blood America, Inc., a Florida corporation ("CBAI"), having a place of business at 1857 Helm Drive, Las Vegas, NV 89119, and on the other hand, AXM Pharma, Inc., a Nevada corporation, having a place of business at 20955 Pathfinder Road, Suite 100, Diamond Bar, CA 91765 ("AXM Pharma") and Newco, a limited liability company organized under the laws of the Peoples Republic of China which is a wholly owned subsidiary of AXM Pharma and which has a place of business at No 2, Feiyun Road, Hunnan New District, Shenyang, China 10168 ("Newco" and, together with AXM Pharma, "AXM"),with respect to the following facts:
LICENSE AND COOPERATION AGREEMENTLicense and Cooperation Agreement • June 14th, 2004 • Forest Laboratories Inc • Pharmaceutical preparations • New York
This License and Cooperation Agreement (the "Agreement") is made and entered into this 28th day of June, 2000, by and between Merz + Co. GmbH & Co., a limited partnership with a limited company as its general partner organized and existing under the laws of Germany, with its principal business office located at Eckenheimer Landstrasse 100-104, D-60318 Frankfurt/Main, Germany ("Merz"), and Forest Laboratories Ireland Limited, a corporation organized and existing under the laws of the Republic of Ireland, with its principal business address located at Clonshaugh Industrial Estate, Clonshaugh, Dublin 17, Republic of Ireland ("Licensee").
AMENDMENT TO THE LICENSE AND COOPERATION AGREEMENTLicense and Cooperation Agreement • May 12th, 2008 • Neurobiological Technologies Inc /Ca/ • Biological products, (no disgnostic substances)
THIS AMENDMENT to that certain April 16, 1998 License and Cooperation Agreement (“Agreement”) by and among Merz + Co. GmbH & Co. (“Merz”), Neurobiological Technologies, Inc. (“NTI”) and Children’s Medical Center Corporation (“CMCC”) is entered into effective as of the 15th day of February, 2008 by and among Merz, NTI and CMCC (each of which may be referred to herein individually as a “Party” and collectively as the “Parties”). Capitalized terms used in this Amendment shall have the meanings ascribed to them in the Agreement.
AGREEMENTLicense and Cooperation Agreement • September 28th, 1998 • Neurobiological Technologies Inc /Ca/ • Biological products, (no disgnostic substances) • California
OMITTED INFORMATION IS THE SUBJECT OF A REQUEST FOR CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSIONLicense and Cooperation Agreement • March 30th, 2010 • Aeterna Zentaris Inc. • Pharmaceutical preparations
Æterna Zentaris GmbH (formerly Zentaris AG) and AOI Pharma, Inc., a wholly-owned subsidiary of Keryx Biopharmaceuticals, Inc. are parties to a License and Cooperation Agreement for Perifosine dated September 18, 2002 (the “Agreement”). The parties wish to amend the Agreement as follows:
THE SYMBOL "*" IS USED THROUGHOUT THIS EXHIBIT TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. LICENSE AND COOPERATION AGREEMENT This License and Cooperation Agreement (the "Agreement") is made and...License and Cooperation Agreement • September 28th, 1998 • Neurobiological Technologies Inc /Ca/ • Biological products, (no disgnostic substances) • New York
EXHIBIT 10.18 THE SYMBOL '*' IS USED THROUGHOUT THIS EXHIBIT TO INDICATE THAT A PORTION OF THE EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. LICENSE AND COOPERATION AGREEMENT This License and Cooperation Agreement (the...License and Cooperation Agreement • January 19th, 2000 • Neurobiological Technologies Inc /Ca/ • Biological products, (no disgnostic substances) • New York
Amendment to License and Cooperation Agreement for Perifosine between Æterna Zentaris GmbH (formerly Zentaris GmbH) Weismüllerstraße 50License and Cooperation Agreement • May 10th, 2011 • Keryx Biopharmaceuticals Inc • Pharmaceutical preparations
WHEREAS Zentaris, as successor in interest to Zentaris AG, and AOI have signed a License and Cooperation Agreement for Perifosine (herein the Agreement) on September 18, 2002;
